![An elderly man smiling looking up at doctor as she holds his hand.](/sites/default/files/styles/1_1_320x320/public/2024-03/man-smiling-doctor-holding-hand.jpg?h=140710cd&itok=KuSzGdOi 320w, /sites/default/files/styles/1_1_640x640/public/2024-03/man-smiling-doctor-holding-hand.jpg?h=140710cd&itok=YFCZGv86 640w)
Frontotemporal Dementia: Diagnosis, Trials & Treatment
Thursday, September 26, 2024
1:00 pm EST (please adjust for your time zone)
Featuring
TBD
Zoom In on Dementia & Alzheimer's is a monthly virtual discussion series with world-class expert research scientists to keep you informed about the latest breakthroughs and findings in the field—from treatments and genetics to risk reduction, supplements, and more.
Each session will include a live Q&A where you can ask your questions directly of the experts. All sessions will be recorded and available to watch on demand.
Thursday, September 26, 2024
1:00 pm EST (please adjust for your time zone)
Featuring
TBD
Join Cognito Therapeutics CEO, Brent Vaughan to talk about the pivotal HOPE Study, currently open for recruitment, which uses an investigational medical device consisting of headphones and eyewear to deliver sensory stimulation treatment in the comfort of people’s homes. The HOPE Study explores if this approach will potentially prove to slow the progression of mild to moderate Alzheimer’s disease.
On July 2, 2024, the U.S. Food and Drug Administration approved Kisunla (donanemab), a new Alzheimer’s medication shown to slow the progression of the disease. Join our conversation with Dr. Paul Aisen as he details how the drug works, for whom, side effects, what it costs, whether it’s covered by insurance, and how it compares with other new Alzheimer’s medicines.
In 2023, there were 184 trials assessing 143 drugs for the treatment of Alzheimer's disease (AD) and Mild Cognitive Impairment, with more than 60,000 participants required to populate those registered trials at 5684 sites. What is happening in 2024? Find out with Dr. Jeffrey Cummings for the insider’s overview.
Three new drugs for Alzheimer’s disease have been approved, and pharmaceutical companies are currently testing 141 Alzheimer’s drugs in 178 clinical trials. World-renowned expert Dr. Reisa Sperling discusses what might be coming through the treatment pipeline for dementias within the next three years.
There is no wonder drug or miracle cure for Alzheimer’s and related dementias, but research studies show that lifestyle choices can cut down your risk. Join Dr. Richard S. Isaacson as he shares insights on how preventative lifestyle changes and individualized care can meaningfully reduce your dementia risk and benefit your overall health.
Join Dr. Cynthia Lemere, Scientist at Brigham and Women’s Hospital and Associate Professor of Neurology at Harvard Medical School, and host Nancy Lynn of BrightFocus Foundation for a discussion on the rapidly evolving—and complex—landscape of available treatments for Alzheimer’s disease and ask the experts what this means for you or a family member.
This program is supported in part by educational funding provided by:
BrightFocus Foundation is dedicated to reaching millions of people worldwide through its public outreach and education efforts around brain and eye health.